ClinicalTrials.gg
Active, not recruitingNCT05416333(CCCA)Updated Jul 1, 2026

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

An Early Phase 1 interventional study of azelaic acid and usual medication for CCCA in Central Centrifugal Cicatricial Alopecia, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Wake Forest University Health Sciences · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
160th of 204
18 · median 40
Started
2024
with 19 others
Phase 1
31 of 217
4 open now
Primary completion
2026-11
later than 21 of 62 live
Registered
144th of 217
by date
Lead sponsor
6 of 217
Wake Forest University Health Sciences

Among the 217 studies in Alopecia with a site in United States, this one is the 160th largest by enrollment of the 204 interventional ones that give a count, is one of 20 that started in 2024, is one of 31 in phase 1, reaches primary completion later than 21 of the 62 other live ones, and was the 144th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this pilot study is to determine if azelaic acid shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). In this study, the aim is to compare azelaic acid vs placebo since azelaic acid may increase anti-inflammatory effects that affect the hair growth cycle.

Read the detailed description

The management of Central Centrifugal Cicatricial Alopecia (CCCA) is challenging due to limited current treatments and a lack of randomized controlled trials. Management focuses on behavioral and styling modifications, in addition to symptomatic relief. Any potentially damaging hair care practices such as chemical relaxers, heat application to the scalp, and the use of hardening gels and sprays are discouraged. Many commonly used therapies are anti-inflammatory in nature, including intralesional steroids, topical steroids, oral antibiotics and increased frequency of hair washing with antidandruff shampoos. These treatments not only lead to improvement in pruritus and tenderness, but in some cases result in increased hair density. Currently, comparison studies of different treatments for CCCA subjects is limited. The aim is to determine if there is an advantage in using one particular anti-inflammatory therapy over another for relieving symptoms and promoting hair follicle regrowth.

03

Conditions studied

  • Central Centrifugal Cicatricial Alopecia

Browse trials for

Keywords

  • hair growth
  • hair follicle regrowth
  • hair loss regression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women eighteen years of age or older
  • -proven and /or clinical diagnosis of CCCA Stage II-IV
  • on stable treatment without changes for at least three months
  • recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology

Exclusion criteria

Exclusion Criteria:

  • males
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    azelaic acid treatment

    Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.

    Drug: azelaic acid

  • Sham comparator
    control (no additional treatment)

    Subjects will continue to use their current primary provider prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.

    Other: usual medication for CCCA

Interventions

  • Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months

    Also known as: Finacea

  • Otherusual medication for CCCA

    Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months

06

What researchers measure

Primary outcomes

  1. Amount of hair loss regression

    measured by standardized photos and dermatoscope photos

    Time frame: Baseline

  2. Amount of hair loss regression

    measured by standardized photos and dermatoscope photos

    Time frame: Month 2

  3. Amount of hair loss regression

    measured by standardized photos and dermatoscope photos

    Time frame: Month 4

  4. Amount of hair loss regression

    measured by standardized photos and dermatoscope photos

    Time frame: Month 6

Secondary outcomes

  1. Amount of hair regrowth

    measured by standardized photos and dermatoscope photos

    Time frame: Months 2, 4, and 6

  2. Amount of alleviation of signs and symptoms of disease

    Higher scores means worse symptoms and signs of disease - Clinical signs and symptoms of CCCA will be documented by administering a standardized questionnaire to all subjects. Subjects will complete the standardized questionnaire regarding symptoms of their hair loss at the start of the enrollment and every 2 months until the study is completed.

    Time frame: Months 2, 4, and 6

  3. Dermatology Life Quality Index (DLQI)

    Scores of "not at all" to "very much"

    Time frame: Baseline and Month 6

07

Study locations

1 site
  • Wake Forest University Health Scieces
    Winston-Salem, North Carolina 27157, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Nov 2026, 27 months after the start.

Of 33 phase 1 interventional studies under Alopecia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 57. This study's planned 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 13, 2022
StartActual
Aug 12, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05416333
Responsible party
Sponsor
First posted
Jun 13, 2022
Start date
Aug 12, 2024
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 1, 2026

Study contacts

Amy J McMichael, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azelaic acid

Start the discussion